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STATEMENT OF TRANSLATIONAL RELEVANCE 
Our results from testicular germ cell tumor cells, in orthotopic testicular 
tumors and human patient samples indicate an increase in PDGFRβ-AKT 
pathway activity as a new mechanism for developing CDDP-acquired resistance 
in testicular cancer cells. These results reinforce the value of reagents such as 
pazopanib or sunitinib, which combine anti-angiogenic and anti-tumoral effects, 
as resensitizing therapies for the subgroups of poor-prognosis CDDP-resistant 
or refractory testicular cancer patients. 
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Abstract 
Purpose: We examined whether PI3K-AKT or ERK signaling pathways 
could play a role in the development of cisplatin (CDDP) resistance in testicular 
germ cell tumor cells. 
Experimental Design: We compared AKT and ERK activation levels in 
CDDP-sensitive testicular tumor cells and in their corresponding CDDP-
resistant derived cells. We also analyzed these pathways in orthotopic testicular 
tumors and human patient samples. 
Results: Our results indicated that there was overactivation of AKT in 
CDDP-resistant cells compared with sensitive cells, but no effect on activated 
ERK levels. We observed an increase in mRNA and protein levels for PDGF 
receptor β and PDGF-B ligand levels. These were responsible for AKT 
overactivation in CDDP-resistant cells. When PDGFRβ levels were decreased 
by shRNA treatment or its activation was blocked by pazopanib, CDDP-
resistant cells behaved like sensitive cells. Moreover, CDDP-resistant cells were 
more sensitive to incubation with PDGFRβ inhibitors such as pazopanib or 
sunitinib than sensitive cells, a finding consistent with these cells being 
dependent on this signaling pathway. We also found overexpression of 
PDGFRβ and pAKT in CDDP-resistant choriocarcinoma orthotopic tumor versus 
their CDDP-sensitive counterparts. Finally, we found high PDGFRβ levels in 
human testicular tumors, and overexpression in CDDP-resistant testicular 
choriocarcinomas compared with the CDDP-sensitive and non-treated tumors.  
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Conclusion: The PDGFRβ-AKT pathway plays a critical role in the 
development of CDDP resistance in testicular tumoral cells. 
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Introduction 
Cisplatin (CDDP) treatment is the first-line chemotherapy drug used in 
patients affected by various types of tumors, including metastatic testicular and 
ovarian tumors. Testicular germ cell tumors (TGTs) are the main cause of 
cancer in men between 15 and 35 years of age (1). These tumors have 
excellent cure rates, with more than 90% of patients achieving a complete 
response to CDDP-based treatment, either alone or combined with surgery. 
Metastatic TGT has the highest cure rate, with a survival rate of 80%. However, 
a proportion of patients relapse or develop refractory diseases following CDDP 
treatment. For these patients, any new treatment would be considered an 
alternative treatment and, therefore, poor prognosis is often the result (2).  
Resistance to chemotherapy is one of the major causes of death in 
cancer patients. The cellular mechanisms for CDDP resistance involve a 
decrease in drug uptake or an increase in its expulsion from tumor cells, CDDP 
inactivation due to binding to sulfur-rich proteins, alterations in the capacity of 
DNA repair or a lack of detection of DNA damage, and a failure to enter cell 
death after DNA damage (3-5). The latter mechanism may result from different 
alterations in tumors, including induction of anti-apoptotic factors or decrease in 
pro-apoptotic factors, but it may also be due to alterations in signal transduction 
pathways that normally regulate apoptosis, survival and proliferation (5). 
Therefore, tumors that present wild-type p53, a key protein for inducing 
apoptosis after DNA damage, respond well to CDDP compared with those 
tumors that present p53-inactivating mutations. This is seen in TGTs that are 
particularly sensitive to CDDP, since they are one of the few cancers in which 
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p53 is rarely inactivated (6). Activation of p38 MAPK, a kinase involved in 
apoptosis induction, is also altered in CDDP-resistant lung cells (7, 8). Pro-
survival signals, such as PI3K-AKT or ERKs, are overstimulated in some 
CDDP-resistant cells, such as lung or ovarian cell lines (3). However, Fung et al 
described that blocking MEK/ERK led to cellular protection against CDDP-
induced apoptosis in TGT cell lines (9). Our study examines the possible 
contribution of some of these signaling pathways to the acquisition of CDDP 
resistance in human testicular tumor cells.  
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Materials and Methods 
Chemical Compounds 
Pazopanib (Votrient®) and Lapatinib (Tyverb®) were kindly provided by 
GlaxoSmithKline. Sunitinib was kindly provided by Pfizer. Gefitinib (Iressa®) was 
kindly provided by AstraZeneca, Ly2109761 was kindly provided by Eli Lilly, and 
Ly294002 and UO126 were obtained from Calbiochem. All the above 
compounds were dissolved in DMSO. CDDP was provided by Pfizer and was 
diluted in sterile serum. PDGF-BB and FGF-2 were provided by R&D, and EGF 
was provided by Sigma.  
 
Cell culture 
The human teratocarcinoma cell line SuSa, or SuSaS (“S” for sensitive to 
CDDP) (10), and GCT27, or GCT27S cells (from embryonic carcinoma origin) 
(11) were kindly provided by Dr. Yong-Jie Lu (Barts Cancer Institute, Queen 
Mary University of London), as well as their respective CDDP-resistant (“R”) 
derived cell lines (SuSaR and GCT27R) (12, 13). Both cell lines were 
authenticated performing the STR profile in November 2012 by the 
Authentication Services of the Health Protection Agency (HPA) Culture 
Collections, UK. SuSa cells were cultivated in RPMI media (Gibco®) 
supplemented with 20% FCS, while GCT27 cells were cultivated in DMEM 
medium (Gibco®) supplemented with 10% FCS. 50 U/ml penicillin, 50 µg/ml 
streptomycin sulfate and 2 mM glutamine were added to all cell culture media. 
All cells were grown at 37ºC in a humidified atmosphere with 5% CO2. 
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Tumor samples 
 We used two orthotopic testicular GCTs models for our studies: a 
choriocarcinoma (TGT38) and its cisplatin-resistant counterpart (TGT38R), both 
of which have been described in Castillo-Avila et al (14). All animal studies were 
approved by the local committee (IDIBELL) for animal care. 
 
shPDGFRβ lentivirus transduction 
SIGMA MISSION® pLKO.1 lentiviral vectors were used to permanently 
silence PDGFRβ expression in GCT27R cells. The negative vector without 
shRNA sequence (Sigma MISSION® pLKO.1-pure empty vector), was used as 
negative control.  
As these vectors express puromycin resistance, cell lines expressing 
lentiviral vectors were established in constant culture of puromycin-containing 
media (2 µg/ml). To confirm the correct PDGFRβ silencing by lentiviral vectors, 
protein samples from the cell lines were collected and processed in a western 
blot.  
 
Cell viability assay 
Cell viability was determined by measuring the metabolic activity using 
the methyl-thiazole-tetrazolium (MTT) assay (Sigma Chemical). Cells were 
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plated in 96-well plates, 1000 cells per well, in quadruplicate, and allowed to 
grow for 24 h. SuSaS or R and GCT27S or R cells were then treated with 0-10-2 
mg/ml of CDDP for 4 days. DMSO was used as a negative control when a 
different drug was added to the CDDP dose curve in the GCT27S or R cells. 
When appropriate, a constant dose of pazopanib (0.5 µg/ml) or Ly294002 (4 µM) 
was added. Subsequently, when treatment was finished, 10 µM MTT was 
added to each well and incubated for an additional 4 hours. The blue MTT 
formazan precipitate was dissolved in DMSO and the optical density was 
measured (absorbance at 570 nm) on a multiwell plate reader. The pazopanib 
(0-10 µg/ml) curve was measured in the same manner.  
 
Western blot 
Samples from cells or tumors were lysed using RIPA lysis buffer. Protein 
lysates were processed as previously described (14). Antibodies used in this 
study are described in the Supplementary Material section. 
 
Elisa 
Human PDGF-BB protein levels were measured using an Elisa Kit from 
RayBio, following the manufacturer’s instructions. When appropriate, PDGF-BB 
was quantified on cell-cultured media without FBS for 16 h. 
 
Quantitative real-time PCR 
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Total RNA from tumors or cells was extracted using the RNAeasy Plus 
Mini Kit (Qiagen). cDNA was obtained after a reverse transcription reaction 
(High Capacity cDNA Reverse Transcription Kit, Applied Biosystems). Real-time 
PCR of cDNA obtained from tumors or cell lines was carried out as previously 
described (14). The human-specific primers used are described in the 
Supplementary Material section. Results are presented with the values 2(-ΔΔCt) 
relative to the corresponding sensitive phenotype. 
  
Immunohistochemistry in human samples and scoring  
PDGFRβ expression was analyzed on samples representative of 71 
patients diagnosed with non-seminomatous germ cell (NSTGT) tumors, 52 of 
whom were treated with CDDP at the Institut Català d’Oncologia between 1989 
and 2004. Eighteen patients were considered to be CDDP-resistant, defined 
according to whether progression or relapse occurred, despite adequate first-
line chemotherapy treatment. Patients with mature teratoma were not 
considered for analysis. 
Paraffin-embedded sections were deparaffinized in xylene and 
rehydrated in downgraded alcohols and distilled water. Antigen retrieval was 
carried out under high-pressure conditions for 2 minutes in citrate buffer, pH 6. 
Samples were then blocked with 1/50 horse serum for 30 minutes and 
incubated with 1/20 anti-PDGFRβ antibody (Santa Cruz Biotechnology, INC) 
overnight at 4ºC. Sections were incubated with the specific secondary rabbit 
antibody EnVisionTMFLex (Dako), followed by the EnVisionTMFLex DAB 
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developing system (Dako). Samples were counterstained with hematoxylin and 
visualized by light microscopy.  
The intensity of PDGFRβ stain was scored using a grading scale, defined 
as follows: no detectable signal (0 points), low-intensity signal (1 point), 
moderate-intensity signal (2 points), or high-intensity signal (3 points). Labeling 
frequency was scored as the percentage of positive tumoral cells. The 
multiplicative index of intensity and labeling frequency was used in our analysis, 
as previously described (15). 
 
Statistical analyses 
Statistical analysis was carried out using SPSS (SPSS for Windows 13.0, 
SPSS, Inc., Chicago, IL). Statistical significance of differences between groups 
was determined using the Mann-Whitney U test, statistical significance being 
concluded for values of p < 0.05 (*) or p<0.01 (**) relative to the GCT27S value 
in all experiments.  
Dose-response curves and IC50 statistics were generated using 
GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA).. 
 
Results 
To explore the mechanisms involved in CDDP resistance in depth, we 
used already existing CDDP-resistant derived testicular cancer cells. Two cells 
lines were used: GCT27 (named GCT27S when referring to those with 
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increased sensitivity to CDDP) (11) and SuSa (SuSaS, for the sensitive line) 
(10), and their resistant CDDP-derived cell lines GCT27R (12) and SuSaR (13). 
We confirmed resistance by measuring the cell viability of these cell lines over a 
range of CDDP concentrations (Fig. 1A and Fig. 1B). As observed, resistant-
derived cells presented IC50s in CDDP of 2.1·10-4 mg/ml (SD 5.7·10-6) in SuSaR, 
compared with 0.8·10-4 mg/ml (SD 4.6·10-6) in SuSaS normal cells, and 8.5·10-4 
mg/ml (SD 1.4·10-4) in GCT27R, compared with 1.9·10-4 mg/ml (SD 1.3·10-5) in 
GCT27S normal cells. In both cases, the difference was found to be significant 
using the Mann-Whitney U test.  
Next, different signal transduction pathways involved in cell survival and 
CDDP resistance, such as PI3K-AKT or ERKs (5), were analyzed. No 
differences in ERK activation levels between normal and CDDP-resistant cell 
lines (Fig. 1C and D) were detected. In contrast, phosphoAKT levels 
(phosphorylated in serine 473 or in threonine 308) were clearly higher in both 
CDDP-resistant cells than in normal cells. We detected no differences in total 
AKT protein levels between normal and CDDP-resistant cell lines (Fig. 1C and 
D).  
To assess the importance of overstimulation of PI3K-AKT to CDDP 
sensitivity, we incubated GCT27S or R cells over a range of CDDP 
concentrations and in the presence or absence of the pan-PI3K inhibitor, 
Ly294002 (4 μM) (Fig. 2A). GCT27R cells recovered their sensitivity to CDDP 
when PI3K activity was inhibited by 4 μM Ly294002 incubation (7.2·10-4 mg/ml 
SD 1.2·10-4 for GCT27R, 2.2·10-4 mg/ml SD 6.0·10-5 for GCT27R with Ly294002, 
2.0·10-4 mg/ml SD 2.0·10-5 for GCT27S, and 1.5·10-4 mg/ml SD 1.8·10-5 for 
14 
 
GCT27S with Ly294002). These results suggest PI3K dependence on CDDP 
resistance in GCT27R cells. 
 Overstimulation of PI3K/AKT activity could arise from intrinsic activating 
mutations in the PI3K protein, altered function of the antagonist phosphatase of 
PI3K, PTEN, or upstream overstimulation due to one of the multiple receptors 
that signal through the PI3K/AKT signaling pathway. To identify the 
mechanisms involved in overstimulating the PI3K/AKT pathway in CDDP-
resistant cell lines, we first measured the levels of PTEN in GCT27 and SuSa 
cell lines. Levels of this phosphatase were comparable in the CDDP-sensitive 
and CDDP-resistant cells (Fig. 1C and 1D), ruling out the possibility of a 
decrease in PTEN levels as being the molecular target of CDDP resistance. 
Moreover, levels of phosphoAKT decreased after the depletion of growth factors 
(Fig. 2B, DMSO lane in GCT27R cells), indicating that the PI3K pathway was 
not overstimulated by an activating mutation. We then proceeded to treat 
exponential CDDP-resistant GCT27 cells with the following inhibitors of different 
growth factor receptors: sunitinib and pazopanib against PDGF receptors, 
VEGF receptors and the stem cell factor receptor, C-KIT; gefitinib against 
ErbB1 receptor; lapatinib against ErbB1 and ErbB2 receptors; Ly2109761 
against TGFβRII; and the U0126 inhibitor of MEK-1 and Ly294002 inhibitor of 
PI3K activity. The results indicated not only that phosphoAKT levels were 
reduced by Ly294002 inhibitor, as expected, but also that PDGFRs, VEGFR 
and c-KIT inhibitors (sunitinib and pazopanib) blocked AKT activity at a similar 
level (Fig. 2C). In contrast, no effect of ErbBs or TGFβ inhibitors was observed 
in these cells. We also observed a slight decrease in ERK1/2 activity with both 
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the MEK1 inhibitor and sunitinib. To confirm these results, depleted parental or 
CDDP-resistant GCT27 cells were incubated with each of the growth factors 
FGF-2, EGF and PDGF-BB, which are known activators of PI3K. As illustrated 
in Fig. 2B, all these growth factors stimulated ERK1/2 at similar levels in normal 
and CDDP-resistant GCT27 cells. In contrast, AKT was activated only by 
PDGF-BB and, more importantly in GCT27 CDDP-resistant cells. This AKT 
stimulation by PDGF-BB was impeded by pazopanib treatment (data not 
shown). 
Our results suggest a different capacity of stimulation by PDGF receptors 
between CDDP-resistant and normal (parental) cells. To confirm whether this 
was the case, we measured mRNA levels of PDGFRα and PDGFRβ in 
GCT27S and GCT27R cells. As shown in Fig. 3A, there was a 3-fold decrease 
in PDGFRα  levels in resistant cells compared with CDDP-sensitive cells, rather 
than an increase. In contrast, mRNA PDGFRβ levels were 2.5-fold as high in 
GCT27R cells compared with normal cells. The results were confirmed by 
measuring PDGFR protein levels in these cell lines. In CDDP-resistant GCT27 
cells, we found a 4-fold increase in total levels (Fig. 3B), and an increase in the 
amount of PDGFRβ in the plasmatic membrane (Supplementary Fig. 1). 
However, no differences were observed in PDGFRα protein levels (Fig. 3B). We 
also measured mRNA and protein levels for the PDGFRs ligands PDGF-A and 
PDGF-B. As shown in Fig. 3C, mRNA levels for this latter growth factor were 
6.5-fold those in resistant cells, while no significant differences were detected 
for the PDGF-A growth factor. Protein PDGF-B levels measured by Elisa were 
also higher in cell lysates (2.9-fold) and cell-culture media (6.9-fold) for resistant 
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compared with cisplatin-sensitive cells (Fig. 3D). Similar results were obtained 
in SuSa cells (Supplementary Fig. 2). Together, these results indicate that 
CDDP-resistance in testicular tumor cells was associated with an increase in 
the activation of the PDGF-B/ PDGFRβ/PI3K-AKT pathway. 
To confirm that AKT activation by PDGFRβ caused CDDP resistance by 
modifying the potential viability of these cells, we evaluated the effect of the 
PDGFR inhibitor pazopanib (0.5 µg/ml) on the CDDP dose-response curve. 
Pazopanib treatment in normal GCT27 cells did not significantly affect the 
CDDP IC50 (Fig. 4A). In contrast, when pazopanib was added to CDDP-
resistant cells, they recovered sensitivity to CDDP, and an IC50 value similar to 
sensitive cells was noted (7.2·10-4 mg/ml SD 3.4·10-4 for GCT27R, 2.81·10-4 
mg/ml SD 1.4·10-4 for GCT27S and 2.56·10-4 mg/ml SD 1.2·10-4 for GCT27R 
with pazopanib). IC50 values for GCT27R cells were significantly different in the 
presence or absence of pazopanib, but not between GCT27R-pazopanib and 
GCT27S, with or without the inhibitor. These results indicated that blocking 
PDGFRs by pazopanib treatment reverted GCT27 cells to CDDP sensitivity.  
Next, to assess whether PDGFRβ was sufficient to explain CDDP-
resistance, we inhibited its expression in GCT27R cells. By transducing 
lentiviral vectors expressing either PDGFRβ-shRNAs or a negative control using 
an empty vector (EV), GCT27R-EV cells as controls or GCT27R-shPβ cells 
were generated. We used four independent shRNA vectors but only one of 
them (shPβ4) partially reduced PDGFRβ expression protein without having 
effects on PDGFRα (Fig. 4B). This partial blocking of PDGFRβ expression also 
partially blocked phosphoAKT levels (Fig. 4B). As shown in Fig. 4C, decreased 
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PDGFRβ levels in GCT27R-shPβ4 cells caused a partial recovery in CDDP 
sensitivity, indicating that inhibition of this receptor affected CDDP resistance. 
Although the difference in IC50 values between GCT27R and GCT27R-shPβ4 
was not statistically significant, we observed a significant decrease in the 
sensitivity of GCT27R-shPβ4 compared with the resistant cell line when 10-4 
mg/ml CDDP was used. Moreover, at this CDDP concentration, the sensitivity of 
these three cell lines to the drug was linearly proportional to the phosphoAKT 
levels detected by western blot (Fig. 4B and Supplementary Fig. 3).  
We also analyzed PDGF-dependence in CDDP-resistant cells compared 
with normal cells. To this end, we treated GCT27S or R cells with a range of 
concentrations of PDGFR inhibitors (pazopanib, Fig. 4D, or sunitinib, data not 
shown), then studied cell viability. We observed that CDDP-resistant cells were 
more sensitive to these inhibitors, with levels of cell viability inhibition around 
90%, compared with 70% in normal cells (Fig. 4D). These results indicated that 
overexpression of PDGF-B and PDGFRβ in CDDP-resistant cells increases the 
degree of addiction of these cells to follow this pathway. 
To determine whether these in vitro associations between acquired-
cisplatin resistance and activation of the PDGFR pathway were also present in 
tumors, we analyzed PDGFR expression in an orthotopic model of testicular 
germ cell choriocarcinoma tumor (TGT38) and its CDDP-resistant counterpart 
(TGT38R). These resistant tumors were generated in our laboratory using a 
mouse model bearing a TGT38 tumor subjected to prolonged CDDP treatment 
(14). We did not detect differences in mRNA or protein levels for the PDGFRs 
ligand PDGF-B in this model (Supplementary Fig. 4). mRNA levels for PDGFRα 
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were found to be equal in TGT38 and TGT38R tumors (Fig. 5A). In contrast, a 
2.2-fold increase in PDGFRβ mRNA levels was found in resistant tumors 
relative to the CDDP sensitive tumors. This result was confirmed by western 
blot analysis of PDGFRβ protein levels. Additionally, a 3-fold increase in 
PDGFRβ expression levels was observed in the CDDP-resistant tumor along 
with a 2-fold increase in pAKT levels (Fig. 5B), confirming the relevance of the 
activation of the PDGFRβ-pAKT pathway in conferring cisplatin resistance.  
Finally, we analyzed PDGFRβ expression in samples from testicular 
tumors patients. To achieve this, immunohistochemistry for this receptor was 
performed on samples from patients affected by different non-seminoma 
testicular germ cell tumors (NSTGTs), which have different histological 
components and responses to the CDDP treatment. The intensity of PDGFRβ 
staining was characterized as undetectable, low, moderate, or high, as 
illustrated in Fig. 5C. The analysis of these samples indicated that 75% of the 
NSTGT patients expressed moderate or high levels of PDGFRβ, although there 
was no difference between the CDDP-sensitive and CDDP-resistant 
phenotypes. However, when we focused our analysis on the patients who 
presented the choriocarcinoma histological component, as a pure or mixed 
testicular tumor, we observed that 80% of the CDDP-sensitive patients 
expressed moderate or high levels of PDGFRβ. In contrast, in the CDDP-
resistant patient group, 100% of patients expressed moderate or high levels of 
this receptor. The multiplicative index considering intensity and the percentage 
of positive cells revealed no differences between CDDP-treated and untreated 
patients or between sensitive and resistant patients. In contrast, patients with 
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resistant choriocarcinomas had a higher index than sensitive choriocarcinomas, 
and a significantly higher index than those untreated patients (Fig. 5D). 
 
Discussion 
This study has shown that an increase in activity of the PDGFRβ-AKT 
CDDP pathway is a hitherto unidentified mechanism of CDDP resistance in 
testicular cancer cells. Activation of PI3K as a mechanism of CDDP resistance 
has been previously described. For example, the increased activation of pAKT 
in human lung tumor tissues is inversely correlated with CDDP sensitivity in 
their primary derived culture counterpart (16). Moreover, a high level of PI3K 
activity in NSCLC CDDP-resistant patients through overexpression of ErbB2 
receptor (17), or through EGFR/Her3 in glioma and ovarian cancer cells has 
also been described (18). Another mechanism involved in cisplatin resistance is 
the downregulation of PTEN by induction of microRNAs, such as miR-214 (19) 
and miR-93 (20) in ovarian cells, or miR-221 in osteosarcoma cells (21). In 
cisplatin-resistant testicular cancer cells, AKT phosphorylates p21 and induces 
its cytoplasmic accumulation, protecting cells from cisplatin-induced apoptosis 
(22). For PDGF factors, an autocrine loop involving PDGF-BB induction in lung 
cancer stem cells resistant to CDDP (23), in glioma CDDP-resistant cell lines 
(24), and in tumoral hepatic progenitor cells resistant to CDDP under hypoxia 
(25) has been described. These last two studies also describe PDGF-BB-
induced AKT overactivation in resistant cells and its importance to the resistant 
phenotype. Moreover, stimulation of PI3K by PDGF renders human ovarian 
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carcinoma cells resistant to paclitaxel (26). However, to our knowledge, this is 
one of the first times that not only an autocrine PDGF loop, but also regulation 
of PDGFR expression have been implicated in CDDP resistance. The molecular 
mechanisms contributing to this response require further investigation. We did 
not detect any differences in the methylation of the PDGFRβ promoter (data not 
shown), a classic mechanism known to induce or repress gene expression. 
Neither were there any differences in the regulation of PDGF-BB-PDGFRβ-
pAKT activation by the TGFβ pathway (Fig. 2), as described in glioma models 
(27). Nevertheless, other mechanisms could be involved, such as microRNA 
regulation or transcription factor activity. All of these mechanisms are regulated 
by CDDP in various tumor cell types (15, 28). 
Our results indicate that sensitivity to CDDP depends on the 
phosphoAKT levels in the cells. In fact, in testicular tumor cells, we observed a 
perfect correlation between phosphoAKT levels and cell viability upon CDDP 
treatment (Supplementary Fig. 3). Moreover, resistant cells recovered their 
sensitivity to CDDP when levels of phosphoAKT were reduced by Ly294002. 
Thus, phosphoAKT seems to be a key factor for CDDP resistance in testicular 
tumor cells, the signaling pathway being regulated by PDGFRβ. The 
immunohistochemistry results from our TMA assay revealed no correlation 
between PDGFRβ expression and resistant or refractory testicular tumors. Only 
in tumors with the choriocarcinoma component, the least common but most 
aggressive non-seminomatous testicular tumor component, the resistance to 
CDDP was correlated with higher PDGFRβ expression. This is the same 
histological component as in the orthotopic tumors in which we found PDGFRβ 
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overexpression in the CDDP-resistant phenotype. However, several signaling 
pathways can induce stimulation of phosphoAKT levels. The PDGFRβ pathway 
was identified in testicular tumor cells and choriocarcinoma tumors, but other 
signaling pathways (such as PDGFRα, c-KIT, ErbBs) could contribute to AKT 
activation in other testicular tumors subtypes and may explain the lack of a 
close correlation between PDGFRβ expression and CDDP resistance in our 
TMA results. Moreover, despite our results concerning phosphoAKT, it is certain 
that patients with CDDP-resistant tumors have more than one mechanism of 
resistance. This adds to the complexity of interpreting the analytical results from 
patient samples (5). 
We detected high levels of PDGFRβ in tumor cells from different types of 
testicular tumors. These results indicate that compounds such as sunitinib or 
pazopanib, in addition to their anti-angiogenic response, also directly affect 
testicular tumor cells by blocking these PDGFRs. Sunitinib as a single agent 
was tested in three clinical trials of refractory GCT (29-31), giving modest 
results, with only a few cases of short-duration disease stabilization followed by 
rapid progressive disease in two studies (29, 31), but with three temporary 
partial responses (9%) and 41% of cases of stable disease in the other (30). 
Moreover, there was a decrease in the frequency of tumor markers following 
sunitinib treatment, suggesting that the targets of sunitinib may still be important 
in GCT biology (29, 31). Our results also indicate that CDDP-resistant testicular 
tumor cells are more sensitive to pazopanib or sunitinib than CDDP-sensitive 
cells. These findings indicate that the cells become addicted to PDGF/PDGFR 
pathway and can explain our group’s previous results concerning sunitinib 
22 
 
response in CDDP-resistant tumors compared with CDDP-sensitive (14). 
Similar results have been reported in glioma cells that overexpress PDGF-BB 
and subsequently become more sensitive to PDGFR inhibitors (24). Thus, our 
findings reinforce the value of these anti-angiogenic reagents as resensitizing 
therapies for subgroups of CDDP-resistant or refractory patients.  
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Figure Legends 
Figure 1. CDDP-resistant cells present high levels of phosphoAKT.  
A and B) Parental sensitive, S, or resistant, R, GCT27 (A) or SuSa (B) 
testicular tumor cells incubated for 4 days in the absence or presence of a 
range of CDDP concentrations. Cell viability measured by MTT assay. Results 
are expressed relative to 0 mg/ml CDDP. Each data point represents the mean 
and standard deviation (SD) of four independent determinations.  
C and D) Expression of phosphorylated Ser473 AKT (p473AKT), 
phosphorylated Thr308 AKT (p308AKT), total AKT, phosphorylated ERK1/2 
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(pERK1/2), total ERK1/2, PTEN and tubulin in GCT27S and R cells (C) and in 
SuSaS and R cells (D) analyzed by western blot. A blot representative of five 
independent experiments is shown. 
 
Figure 2. Blocking PI3K activity restores CDDP sensitivity and 
phosphoAKT levels depend on PDGF receptors. 
A) GCT27S and R cells incubated for 4 days in the presence of the indicated 
concentrations of CDDP and in the absence (DMSO), or presence of 4 μM 
Ly294002 PI3K inhibitor. Cell viability was measured by MTT assay. Results are 
expressed as relative to CDDP 0 mg/ml dose condition. Each data point 
represents the mean and SD of four independent determinations. Differences 
between GCT27R and GCT27R+Ly294002 were considered statistically 
significant when p < 0.05 (*) (Mann-Whitney U test).  
B) Growth factor-depleted GCT27S or GCT27R cells stimulated for 15 min in 
the absence (DMSO) or presence of 20 ng/ml PDGF-BB, 20 ng/ml EGF or 20 
ng/ml FGF-2. Cells were lysed, and phosphorylated AKT (p473AKT), total AKT, 
phosphorylated ERK1/2 (pERK1/2), total ERK1/2 and actin expression analyzed 
by western blot. A blot representative of two independent experiments is shown. 
C) Exponential GCT27R cells incubated for 3 h in the absence (DMSO) or 
presence of 10 µM U0126 (MEK inhibitor), 15 µM Ly294002 (PI3K inhibitor), 5 
µg/ml  pazopanib (PDGFRs and c-KIT inhibitor), 10 µM sunitinib (PDGFRs and 
c-KIT inhibitor), 2 µM Ly2109761 (TGFβRII inhibitor), 10 µM gefitinib (ErbB1 
inhibitor) or 10 µM lapatinib (ErbB1 and ErbB2 inhibitor). Cells lysed and 
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phosphorylated AKT (p473AKT), total AKT, phosphorylated ERK1/2 (pERK1/2), 
total ERK1/2 and actin expression analyzed by western blot. A blot 
representative of two independent experiments is shown. 
 
Figure 3. PDGFRβ and its ligand PDGF-BB are over-expressed in GCT27R 
cells.  
A) mRNA levels of human PDGFRα and β analyzed by quantitative real-time 
PCR in GCT27S and R cells. Results are expressed as the mean and SD of 
mRNA expression in 5 GCT27R samples relative to mRNA expression levels in 
4 GCT27S samples.  
B) PDGFRα, PDGFRβ and actin protein levels analyzed by western blot in 
GCT27S and R cells. A blot representative of four independent experiments is 
shown. Densitometric quantification of PDGFRβ and PDGFRα from western 
blots shown as the mean and SD of 4 independent samples, represented as 
arbitrary units relative to GCT27S cell group mean.  
C) mRNA levels in human PDGF-A and B analyzed by quantitative real-time 
PCR in GCT27S and R cells. Results are expressed as the mean and SD of 
mRNA expression in 5 GCT27R samples relative to mRNA expression levels in 
4 GCT27S samples.  
D) Human PDGF-BB protein levels measured by Elisa in cell lysates (pg of 
PDGF-BB / g of protein) and in cell culture media (pg of PDGF-BB / 106 cells). 
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Results are expressed as the mean and SD of three independent samples for 
each cell line. 
 
Figure 4. Blocking of PDGFRβ activity reverts CDDP resistance.  
A) GCT27S and GCT27R testicular tumor cells incubated for 4 days in a range 
of concentrations of CDDP in the absence or presence of 0.5 µg/ml pazopanib. 
Cell viability measured by MTT assay. Results are expressed relative to those 
for 0 mg/ml of CDDP condition. Each data point represents the mean and SD of 
6 determinations measured in duplicate. Differences between GCT27R and 
GCT27R + pazopanib were considered statistically significant when p < 0.05 (*) 
(Mann-Whitney U test).  
B) PDGFRα, PDGFRβ, phosphorylated AKT (p473AKT), total AKT, 
phosphorylated ERK1/2 (pERK1/2), total ERK1/2 and actin protein levels 
analyzed by western blot in GCT27S, GCT27R and GCT27R-shPβ4 cell lysates.  
C) GCT27S, GCT27R and GCT27R-shPβ4 cells incubated for 4 days, in the 
absence or presence of a range of CDDP concentrations. Cell viability was 
measured by MTT assay. Results are expressed relative to CDDP, 0 mg/ml 
dose condition. Each data point represents the mean and SD of 4 independent 
determinations.  
D) GCT27S or R testicular tumor cells incubated for 4 days in the absence or 
presence of a range of concentrations of pazopanib. Cell viability measured by 
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MTT assay. Results are expressed relative to CDDP, 0 mg/ml dose condition. 
Each data point represents the mean and SD of 3 determinations. 
 
Figure 5. PDGFRβ overexpressed in CDDP-resistant orthotopic testicular 
tumors and in human choriocarcinoma tumors.  
A) mRNA levels of human PDGFRα and β analyzed by quantitative real-time 
PCR from samples of orthotopic human choriocarcinoma tumors CDDP-
sensitive (TGT38) or its CDDP-resistant version (TGT38R). Results are 
expressed as the mean and SD of mRNA expression in 4 independent TGT38R 
tumors relative to mRNA expression levels in 4 independent TGT38 tumors.  
B) Expression of human protein PDGFRα and β receptors, pAKT (p473AKT) 
and tubulin analyzed by western blot in two samples from TGT38 
choriocarcinoma orthotopic testicular tumors (lanes 1 and 2) and two from 
CDDP-resistant TGT38R tumors (lines 3 and 4). Densitometric quantification of 
PDGFRβ from western blots shown as the mean and SD of 5 independent 
TGT38 tumors and 4 independent TGT38R tumors, represented as arbitrary 
units relative to the TGT38 group mean.  
C) Examples representative of no staining (a), and low (b), moderate (c) and 
high (d) levels of positive PDGFRβ immunostaining in NSTGT patients samples.  
D) Quantification of PDGFRβ levels (using the multiplicative index of the 
intensity of the stain and the labeling frequency) in tumor tissue sections from 
non-CDDP-treated patients, CDDP-sensitive or CDDP-resistant general non-
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seminomatous germ cell tumor patients (NSTGT) and CDDP-sensitive or 
CDDP-resistant choriocarcinoma tumor patients. Data analyzed from 19 good-
prognosis non-seminomatous germ cell tumor patients, 34 CDDP-sensitive and 
18 CDDP-resistant non-seminomatous germ cell tumor patients, and 10 CDDP-
sensitive and 6 CDDP-resistant choriocarcinoma tumor patients. Results are 
expressed as the mean and SD.  
 
 





